Bioresorbable Medical Materials Patents: Leaders & White Space 2026
- Filing peaked in 2019 at 13 families, then went quiet at the 2022 midpoint before picking up again — a pattern more consistent with a field in a second wave than one plateauing.
- The five most-cited records are all pre-2005 filings, led by a 503-citation biodegradable implant patent — foundational art that current filers still have to design around.
- No assignee shows filing activity in the latest year, including the most active historical names, which points to either a lag in publication or a genuine gap ready for a new entrant to claim.
What this dataset covers
This landscape covers 138 patent families filed against bioresorbable and biodegradable implant materials, spanning degradation rate control, mechanical retention, inflammatory response, magnesium alloy implants and byproduct clearance. The search combines title/abstract terms for bioresorbable and resorbable-polymer implants with IPC classes A61L27, A61L31 and C08G63, so the set is weighted toward material composition and surface treatment claims rather than device geometry alone.
Coverage runs from 2015 through the 2026 data cut-off. Because publication typically lags filing by around 18 months, the most recent one or two years in any trend line will understate real filing activity — treat the tail of the chart as a floor, not a ceiling.
Filing trend and technology composition
Two views of the same 138-family dataset: how filing volume has moved year over year, and which IPC subclasses carry the claim density.
Filing rose to a 2019 peak, then a quiet middle
Filings climbed from 6 in 2017 to a peak of 13 in 2019, then fell away — the midpoint year of 2022 recorded zero filings in this dataset before activity resumed. That shape is more consistent with a technology working through a first wave of foundational claims and a second cohort now entering than with steady, mature growth.
A61L and A61F dominate; the polymer chemistry classes are thinner
A61L (sterilising and disinfecting, which in this corpus captures bioresorbable material treatment) appears in all 138 records by construction of the search, with A61F (implants and prostheses) close behind at 69. Beyond that the volume drops sharply: B29C shaping methods and C08G condensation polymers sit at 12 each, C08F addition polymers at 10, and A61K medicinal preparations and C08K polymer additives at 9 apiece. That gap between the implant-function classes and the underlying polymer-chemistry classes is where claim density thins out.
Shares are the percentage of the 138 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Bioresorbable Medical Materials with Eureka
This page is one run against one query. Ask Eureka your own question about bioresorbable medical materials and every answer comes back with the patent numbers behind it.
Try EurekaThe claims setting the boundaries
Biodegradable magnesium alloy implant — BIOTRONIK AG
A biodegradable implant formed from a magnesium alloy carrying 3 to 7% by weight zinc and 0.001 to 0.5% by weight calcium, with total impurities held to no more than 0.0048% by weight. The claim specifically constrains impurity elements that promote electrochemical potential differences or intermetallic phase formation, which is the mechanism that drives uneven, unpredictable corrosion in magnesium implants.Filed 2019-09-19 · BIOTRONIK AG
View full filing| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5876452A | Biodegradable implant | 503 |
| 2 | US6511511B1 | Fiber-reinforced, porous, biodegradable implant device | 310 |
| 3 | US5492697A | Biodegradable implant for fracture nonunions | 291 |
| 4 | US5977204A | Biodegradable implant material comprising bioactive ceramic | 257 |
| 5 | US20040220660A1 | Bioresorbable stent with beneficial agent reservoirs | 194 |
| 6 | US6783712B2 | Fiber-reinforced, porous, biodegradable implant device | 165 |
| 7 | US6344496B1 | Biodegradable implant material comprising bioactive ceramic | 136 |
| 8 | US20150081000A1 | Braided scaffolds | 112 |
| 9 | US20030075822A1 | Fiber-reinforced, porous, biodegradable implant device | 98 |
| 10 | WO1998053768A1 | Fiber-reinforced, porous, biodegradable implant device | 88 |
Citation counts accumulate over time and favour older filings; read them as a measure of influence on the field, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Reading the filing pattern
What the trend, the citation concentration and the co-filing pairs suggest about how this field is structured.
A second wave, not a steady climb
The jump to 13 families in 2019 followed by a dead midpoint year in 2022 is not the profile of gradual maturation. It reads as an initial cluster of foundational filings followed by a lull, with renewed activity only now showing up in the still-incomplete recent years.
Old art still anchors the field
The most-cited record in this dataset draws 503 citations, and the next four most-cited records are also older filings. New entrants are building on top of a small set of foundational patents rather than a broad, recent prior-art base.
Collaboration is limited and concentrated
Only 10 co-assignee pairs appear across 138 families, and the strongest single pairing accounts for 8 shared filings. Most assignees in this space file alone rather than through joint development arrangements.
US and EPO carry most of the volume
The United States accounts for the largest share of receiving-office filings at 39, with Europe at 30 and WIPO/PCT filings at 24. Australia, Canada and Austria each carry single-digit-to-low-double-digit counts, indicating those are secondary rather than primary filing jurisdictions for this technology.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to bioresorbable medical materials, with the prior art for and against each one.
Who holds ground, and where nobody is filing yet
Recent-year momentum data shows zero filings in the latest year for every assignee tracked, including the most historically active names — a signal worth treating carefully given publication lag, but also a genuine opening for whoever files next.
Osteobiologics Inc
The strongest co-assignee pairing in the dataset links Osteobiologics Inc with American Biomaterials Corp at 8 shared filings, the densest collaborative relationship in the set. Osteobiologics also shows a separate pairing with an individual inventor, Leatherbury Neil C.
Biotronik AG
Biotronik's magnesium-alloy implant filing is the representative record for this dataset, narrowing impurity content to control corrosion behaviour — a claim strategy other magnesium-alloy filers will need to design around or invalidate.
A geographically mixed field
Assignees including Ghent University, Boston Scientific International, Olympus, McGill University, Cordis Neurovascular and Zimmer GmbH appear in the ranking, indicating the field draws filers from academic, device-major and specialist implant backgrounds rather than one dominant region.
| Assignee | Recent year | YoY |
|---|---|---|
| OSTEOBIOLOGICS INC | 0 | — |
| Ghent University | 0 | — |
| Boston Scientific International | 0 | — |
| AMERICAN BIOMATERIALS CORP | 0 | — |
| Olympus Corporation | 0 | — |
| BIOMET INC | 0 | — |
| McGill University | 0 | — |
| Cordis Neurovascular | 0 | — |
Where to take this
The dataset points to specific next steps depending on whether you are scoping freedom-to-operate or looking for a filing gap.
Check the magnesium alloy impurity claims
If your work touches magnesium-alloy implants, the Biotronik impurity-threshold claim is a specific boundary to map against your own composition before filing.
Explore claims in Eureka →Probe the polymer-chemistry classes for gaps
C08G, C08F and C08K each sit well below the implant-function classes in volume, which is where a narrowly drafted composition claim may still have room.
Run a white-space search in Eureka →Watch for the delayed 2025-2026 cohort
Given the typical 18-month publication lag, filings from the last two years are undercounted here — recheck this trend in two quarters before concluding the field has cooled.
Track filing trends in Eureka →Common questions on bioresorbable medical materials patents
In this dataset, bioresorbable medical materials are captured under IPC classes A61L27 and A61L31 (materials for prostheses and surgical dressings) and C08G63 (condensation polymers used in degradable implants), combined with title/abstract language around biodegradable implants and resorbable polymer implants. This spans magnesium alloys, resorbable polymers and bioactive ceramics used in implants that are designed to degrade in the body over a defined period. The classification is deliberately broad on material type but narrow on function, which is why implant-function classes like A61F appear alongside the sterilising/material class A61L at high frequency.
The historical filing activity in this dataset is led by a mix of specialist implant developers and larger device and academic institutions, including Osteobiologics Inc, American Biomaterials Corp, Ghent University, Boston Scientific International, Olympus and Biotronik. No single assignee dominates by volume; the field instead shows a leader-plus-long-tail pattern with most co-filing concentrated in a handful of pairs rather than broad industry consortia. Notably, none of the assignees tracked show filings in the most recent year, though this is likely affected by publication lag rather than an actual halt in activity.
Filing volume in this dataset rose to 13 families in 2019 from 6 in 2017, then fell to zero at the 2022 midpoint before a small uptick appears in the most recent years. This pattern is consistent with an initial wave of foundational composition and process claims being filed and prosecuted, followed by a lull while those patents worked through examination, with a second cohort of filers now entering. Because publication lags filing by roughly 18 months, the apparent drop in 2022 and the low count shown for 2026 should not be read as the field cooling — the true recent-year volume is understated in any patent trend chart.
US20190284671A1, assigned to Biotronik AG and filed 2019-09-19, claims a biodegradable implant made from a magnesium alloy with 3 to 7% zinc by weight and 0.001 to 0.5% calcium by weight, with total impurity content capped at no more than 0.0048% by weight. The claim specifically targets impurity elements known to promote electrochemical potential differences and intermetallic phase formation — the mechanisms behind uneven, unpredictable corrosion in magnesium implants. Anyone developing a magnesium-alloy bioresorbable implant should compare their alloy composition and impurity profile against this claim's numeric thresholds directly, since the claim is drafted around specific weight-percentage ranges rather than a broad compositional class.
The technology composition data shows a sharp drop-off between implant-function classes (A61L at 138, A61F at 69) and the underlying polymer-chemistry classes (C08G, C08F and C08K each in single or low double digits). That gap suggests degradation-rate tuning agents, byproduct clearance kinetics, and inflammatory-response-specific coatings are comparatively under-claimed relative to the implant-form claims built on top of them. Co-filing data also shows only 10 co-assignee pairs across 138 families, indicating limited collaborative claim-building — a further sign that adjacent polymer-chemistry angles have not been exhaustively staked out by joint filers.
Research Bioresorbable Medical Materials in depth with Eureka
Go past this page: query the whole bioresorbable medical materials corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.